Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating because — you guessed it — the unrelenting routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? Well, what can you do except fire up the coffee kettle and quaff some cups of stimulation. Cinnamon coffee roll is our flavor today, for those who track this sort of thing. Meanwhile, here are some tidbits. Hope you have a smashing day and keep us in mind if you hear anything interesting …

Novartis increased pressure on Roche’s aging roster of big-selling drugs by becoming the latest company to win European approval for a lower-price version of the Rituxan drug, Reuters tells us. The drug, which is used to treat blood cancer and immunological diseases and is also known as MabThera, racked up $7.5 billion in global sales in 2016 and costs tens of thousands per year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.